FTC Final Order with Baxter International and Claris Lifesciences Preserves U.S. Competition for the Injectable Drugs Intravenous Fluconazole and Intravenous Milrinone

Following a public comment period, the Federal Trade Commission has approved a final order designed to remedy the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business. As announced in July 2017, the complaint alleges Baxter’s proposed acquisition would likely reduce current competition in the U.S. market for the antifungal […]

FTC Amicus Brief Urges Appeals Court to Correct Legal Errors in District Court’s Antitrust Analysis of Reverse-Payment Agreement

The Federal Trade Commission filed an amicus brief with the U.S. Court of Appeals for the Third Circuit urging the court to correct four legal errors in a district court’s antitrust analysis of an alleged reverse-payment agreement involving brand-name pharmaceutical company GlaxoSmithKline and generic pharmaceutical companies Teva Pharmaceuticals and Anchen Pharmaceuticals. The amicus brief, filed […]

FTC Approves Final Order Settling Charges that Actavis, Inc.’s Acquisition of Warner Chilcott plc Would Be Anticompetitive in Four Current and Future Drug Markets

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Actavis, Inc’s proposed acquisition of Warner Chilcott plc would reduce competition in the U.S. markets for four current and future pharmaceuticals. They are: Generic Femcon FE, a chewable oral contraceptive tablet that contains progestin and estrogen; Loestrin 24 […]

FTC Approves Final Consent Order in Case of Pfizer Inc. and Wyeth

Following a public comment period, the Federal Trade Commission has approved a final consent order regarding Pfizer Inc.’s recent acquisition of Wyeth, and responses to members of the public who provided comments. The final order settles charges that the transaction as proposed would have been anticompetitive in a number of markets for animal vaccines and […]

FTC Order Restores Competition Lost Through Schering-Plough’s Acquisition of Merck

Merck & Co., Inc. must sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and Schering-Plough must sell its assets related to significant drugs for nausea and vomiting in humans, in order for Schering-Plough to complete its proposed $41.1 billion acquisition of Merck, the Federal Trade Commission announced today. The […]

Statement of the FTC’s Bureau of Competition Regarding the Announcement that CSL Will Not Proceed with its Proposed Acquisition of Talecris Biotherapeutics

Following the Federal Trade Commission’s filing of a lawsuit to block the transaction, CSL Limited announced on June 8, 2009, that it will not proceed with its proposed $3.1 billion acquisition of Talecris Biotherapeutics. The FTC’s complaint charged that the deal would be illegal and would substantially reduce competition in the U.S. markets for four […]